1146699-66-2 | Bms-708163

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$13.00	$9.00
5mg	99%	in stock	$31.00	$22.00
10mg	99%	in stock	$44.00	$31.00
50mg	99%	in stock	$125.00	$87.00

Description

• Catalog Number: AA19236
• Chemical Name: Bms-708163
• CAS Number: 1146699-66-2
• Molecular Formula: C20H17ClF4N4O4S
• Molecular Weight: 520.885
• MDL Number: MFCD13195458
• SMILES: NC(=O)[C@H](N(S(=O)(=O)c1ccc(cc1)Cl)Cc1ccc(cc1F)c1nocn1)CCC(F)(F)F

Computed Properties

• Complexity: 792
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 11
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 9
• XLogP3: 4

Upstream Synthesis Route

Avagacestat is a potent chemical compound utilized in the field of chemical synthesis for its role as a γ-secretase inhibitor. This inhibitor function is pivotal in the manipulation of protein processing, particularly the cleavage of amyloid precursor protein. By effectively inhibiting γ-secretase, Avagacestat can modulate the generation of amyloid beta peptides, making it a crucial tool in the study of neurodegenerative diseases such as Alzheimer's. Additionally, Avagacestat's application extends to drug development, where its ability to influence protein cleavage pathways plays a significant role in designing novel therapeutic agents targeting various diseases characterized by aberrant protein processing.

Literature

• Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat.

  Toxicological sciences : an official journal of the Society of Toxicology 20180601

• Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.

  Journal of medicinal chemistry 20130711

• Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

  Archives of neurology 20121101

• Degradation kinetics and mechanism of an oxadiazole derivative, design of a stable drug product for BMS-708163, a γ-secretase inhibitor drug candidate.

  Journal of pharmaceutical sciences 20120901

• Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.

  Journal of medicinal chemistry 20120412

• Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.

  The Journal of pharmacology and experimental therapeutics 20111201

• Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.

  Journal of medicinal chemistry 20111124

• Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100901

• Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.

  Journal of medicinal chemistry 20091022